EBNA1 Inhibitor Crystalline Forms for EBV Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments are ineffective in blocking or eliminating Epstein-Barr Virus (EBV) latent infection, which is oncogenic and associated with various cancers and immune disorders, as existing antivirals cannot prevent the establishment of latent EBV infection in B-lymphocytes and other cells.

Innovation Solution

Development of 2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoic acid crystalline solid and its pharmaceutical compositions that can effectively treat and prevent EBV infections by targeting EBNA1 activity, including both lytic and latent infections.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing herpesvirus antivirals (e.g., ganciclovir, foscarnet) are used to treat EBV infection, then lytic replication is partially inhibited, but latent infection cannot be blocked or eliminated

Engineering Contradiction:

Improveinhibitory activity against EBV lytic replicationVSAvoidability to block latent infection

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention segments the antiviral approach into two distinct functional components: (1) inhibition of lytic replication through DNA polymerase targeting, and (2) prevention of latent infection establishment through EBNA-1 protein inhibition. This is achieved by using compound (I) which specifically targets EBNA-1, complementing existing antivirals that target lytic replication. The segmentation allows each component to address its specific target without interference, resolving the contradiction between treating lytic and latent phases.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention introduces compound (I) as an intermediary agent that bridges the gap between treating lytic and latent EBV infections. This compound specifically binds to EBNA-1 protein, preventing its interaction with cellular machinery required for latent infection maintenance. By acting as a mediator between the virus and host cell, compound (I) enables blocking of latent infection without affecting lytic replication, thus resolving the contradiction.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If robust immune response is evoked against EBV infection, then viral clearance is enhanced, but establishment of latent infection in memory B-cells still occurs

Engineering Contradiction:

Improveimmune response efficacyVSAvoidpersistence of latent infection in memory cells

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The invention applies preliminary action by administering compound (I) before or during the establishment phase of latent infection. The compound pre-emptively blocks EBNA-1 function, preventing the virus from establishing latent infection in memory B-cells before the immune response can act. This timing strategy ensures that even when the immune system mounts a robust response, the latent infection cannot take hold, resolving the contradiction between immune efficacy and latent infection prevention.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention creates a pharmacological copy of the protective function that the immune system would ideally provide but fails to deliver. Compound (I) mimics the protective effect against latent infection by directly inhibiting EBNA-1, compensating for the immune system's inability to prevent latent establishment. This pharmacological copy works alongside the immune response to ensure both lytic and latent phases are controlled.

Inventive Principle:

Principle #26Copying

3Ease of manufacture

If compound (I) is synthesized as non-crystalline solid, then synthesis flexibility is maintained, but manufacturing scalability and reproducibility are compromised

Engineering Contradiction:

Improvesynthesis flexibilityVSAvoidlarge-scale preparation reproducibility

Core Design Contradiction:

Ease of manufactureVSProductivity

Solution Approach 1:

The invention applies parameter changes by transforming compound (I) from a non-crystalline solid to a crystalline form with specific X-ray powder diffraction patterns. This phase transition changes the physical parameters of the compound, enabling it to be processed more reliably at scale. The crystalline form provides defined melting points, solubility characteristics, and flow properties that are essential for consistent manufacturing, while the chemical synthesis pathway remains flexible.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention utilizes phase transitions by deliberately crystallizing compound (I) into a stable solid form with characteristic diffraction patterns. This phase transition from amorphous to crystalline state improves the compound's physical properties for manufacturing, including stability, solubility, and processability. The defined crystal structure enables reliable scaling from laboratory to industrial production while maintaining synthesis flexibility through standard crystallization protocols.

Inventive Principle:

Principle #36Phase transitions

Data Source

PatentUS12116359B2EBNA1 inhibitor crystalline forms, and methods of preparing and using same

Publication Date: 2024.10.15 WISTAR INSTITUTE

AI summary

The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and/or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.